Aditxt, Inc. (ADTX): M&A transaction — Aditxt subsidiary Pearsanta acquires MDNA's Mitomic testing platform for ~$25M

Aditxt, Inc.

Consideration: 50k shares of ADTX common, warrants for 50k shares, 5k Pearsanta preferred ($25M value), up to $3.2M in transition services.
Amendments to asset purchase agreement removed $500k upfront and $500k closing payments; increased transition services cap from $2.2M to $3.2M.
Platform includes Mitomic Endometriosis Test (blood-based) and Mitomic Prostate Test; pipeline for ovarian, lung, pancreatic, and other cancers.
Also amended Merger Agreement with Evofem to extend proxy statement filing deadline to February 14, 2024.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.95

Aditxt, Inc. completed an acquisition involving MDNA Life Sciences, Inc. for the Company completed its acquisition of the Acquired Assets and issued to MDNA the Company Common Stock, the Company Warrants and the Pearsanta Preferred Stock (closed 2024-01-04).

Action: acquisition
Counterparty: MDNA Life Sciences, Inc.
Consideration: the Company completed its acquisition of the Acquired Assets and issued to MDNA the Company Common Stock, the Company Warrants and the Pearsanta Preferred Stock
Closing: 2024-01-04

Exact text from the filing

On January 4, 2024 (the “ Closing Date ”), the Company completed its acquisition of the Acquired Assets and issued to MDNA the Company Common Stock, the Company Warrants and the Pearsanta Preferred Stock.

View on SEC.gov

31 m&a transactions filed in the last 30 days. Browse all m&a transactions →

Aditxt, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-002360

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.